AI In Endoscopy Market Valued At USD 838.9 Million By 2033

Introduction

The Global AI In Endoscopy Market size is expected to be worth around US$ 838.9 Million by 2033 from US$ 58.1 Million in 2023, growing at a CAGR of 30.6% during the forecast period from 2024 to 2033. In 2023, North America held over 48.7% market share, reaching a revenue total of US$ 28.2 Million.

This growth is driven by advancements aimed at enhancing diagnostics and treatment within gastroenterology. A key factor is the improved diagnostic accuracy facilitated by AI, which aids in detecting and characterizing gastrointestinal anomalies, including cancers. Machine learning algorithms analyze endoscopic images to identify subtle lesions often missed through manual observation, thereby improving diagnostic precision and enabling real-time decision-making during procedures.

Operational efficiency further fuels the market’s expansion. AI aids in optimizing endoscopic tool adjustments and procedural navigation, reducing operation times and lowering healthcare costs. Its ability to process large datasets of patient histories and endoscopic images enables predictive analytics, which forecasts patient outcomes and disease recurrence probabilities. This supports personalized treatment strategies and improves patient care management.

AI is also transforming education and training in the field. Advanced AI-powered simulations offer gastroenterologists and endoscopic surgeons immersive, risk-free learning opportunities by simulating various clinical conditions. Additionally, AI fosters collaboration among medical professionals by integrating diverse data types, such as radiological and histological information, into unified platforms, thereby enabling comprehensive patient evaluations and supporting multidisciplinary discussions.

Recent innovations and regulatory approvals reflect the market’s dynamic evolution. For example, in January 2023, AnX Robotica received FDA de novo clearance for its AI-powered tool, NaviCam ProScan, which employs convolutional neural networks to distinguish between normal and abnormal tissue in images. Similarly, in February 2023, AI MedTech firm Waycen announced a strategic sales partnership with MegaMind to distribute its AI solutions across the Middle East. These milestones highlight the growing adoption of AI technologies in endoscopy and underscore the market’s potential, driven by continuous technological progress.

Key Takeaways

• The global AI in endoscopy market is projected to witness significant growth, with a CAGR of 30.6% from 2024 to 2033.
• Revenue in the AI in endoscopy market is anticipated to increase from USD 58.1 million in 2023 to approximately USD 838.9 million by 2033.
• Gastrointestinal Endoscopy accounted for the largest revenue share among the types of endoscopy, capturing 32.4% of the market.
• Hospitals constituted the dominant end-user segment, commanding 58.2% of the market share.
• CADx (Computer-Aided Diagnosis) retained its dominance within CAD analysis, holding a market share of 43.0%.
• North America maintained its stronghold on the market, representing 48.7% of the revenue share.
• The Services segment emerged as the leading component, contributing 39.7% to the market share.
• Stomach cancer ranks as the fifth most prevalent cancer globally, according to the World Cancer Research Firm.
• Over 40% of the population suffers from functional gastrointestinal disorders (FGIDs), as reported by research published in the Gastroenterology Journal.
• Gastrointestinal cancers are responsible for one out of every three cancer fatalities, according to the International Agency for Research on Cancer.

AI in Endoscopy Statistics

• Esophageal Cancer Detection: AI systems have achieved sensitivity rates up to 98% and specificity rates up to 95%, excelling in early lesion detection and cancer invasion depth determination.
• Early Gastric Cancer (EGC): AI models demonstrate sensitivity as high as 92.2%, effectively distinguishing between EGC and non-cancerous lesions, enabling timely treatment and better prognoses.
• Helicobacter pylori Infection: AI systems outperform endoscopists in detecting this gastric cancer risk factor, with sensitivities and specificities ranging from 85% to 90%.
• Colon Polyp Detection: AI has significantly improved adenoma detection rates (ADR) during colonoscopies, consistently outperforming standard methods in clinical studies.
• Colorectal Lesion Histopathology: AI distinguishes between neoplastic and non-neoplastic polyps with accuracy rates ranging from 78.8% to 94%, aiding precise diagnoses.
• Capsule Endoscopy (CE): AI-supported CE achieves over 90% sensitivity and specificity in detecting abnormalities, including bleeding, ulcers, erosions, and masses.
• Endoscopy Quality Control: AI enhances lesion detection by reducing blind spots and improving inspection quality, ultimately increasing diagnostic accuracy and reliability.

Use Cases

• Enhanced Detection and Diagnosis: AI integration in colonoscopy has revolutionized the detection of preneoplastic lesions, such as polyps, and improved the management of upper digestive tract conditions like gastroesophageal reflux disease, Barrett’s esophagus, and gastric cancer. Utilizing advanced image analysis and pattern recognition, AI enhances diagnostic precision, assisting endoscopists in identifying subtle abnormalities.
• Quality Control in Gastrointestinal Endoscopy: AI systems improve endoscopic procedures by automatically identifying the cecum, monitoring withdrawal speed, and measuring polyp size with high accuracy. These capabilities aid decision-making in polyp management and enhance procedural safety and efficiency by accurately identifying endoscopic equipment.
• Reducing Blind Spot Rates: AI-powered systems, such as WISENSE, significantly reduce blind spots during Esophagogastroduodenoscopy (EGD) by detecting hidden areas in the gastric mucosa. This innovation is vital for early cancer detection, particularly for gastric cancer, where survival rates depend on early diagnosis. AI improves examination thoroughness, benefiting regions with limited training and low disease prevalence.
• Guided Biopsy and Optical Biopsies: AI enables a shift from random to targeted biopsies through Computer-Aided Detection (CADe) systems for early tumor identification and Computer-Aided Diagnosis (CADx) systems for predicting lesion histology without physical biopsies. These tools provide high accuracy, sensitivity, and specificity, improving lesion characterization and treatment strategies.
• Assessing Depth and Boundary of Invasion: AI algorithms predict cancer invasion depth and boundaries in gastric and esophageal cancers with remarkable accuracy by analyzing endoscopic images. These precise assessments support tailored treatment plans, enhancing patient survival rates and ensuring appropriate therapeutic interventions.

Key Player Analysis

• Medtronic: Medtronic has pioneered advancements in AI-driven endoscopy with its GI Genius Intelligent Endoscopy Module, the first AI-powered computer-aided polyp detection system. This innovation enhances visualization during colonoscopy, increasing adenoma detection rates (ADR) by up to 14.4%, which corresponds to a 3% reduction in interval cancer risk for each percentage increase in ADR. This breakthrough technology has significantly advanced early colorectal cancer detection, offering life-saving potential through improved diagnostic accuracy.
• Wision AI: In collaboration with Micro-Tech Endoscopy, Wision AI developed EndoScreener, an FDA-cleared AI-assisted polyp detection software. This system improves adenoma detection by 32% compared to standard procedures, contributing to early detection of colorectal cancer and better patient outcomes.
• Olympus Corporation: Olympus strengthened its presence in AI-powered endoscopy by acquiring London-based Odin Vision, a leader in cloud-AI endoscopy. This GBP 66 million acquisition adds commercially available computer-aided detection/diagnostic (CAD) solutions and a promising pipeline of cloud-enabled applications to Olympus’s portfolio. The integration of AI aims to improve diagnostic accuracy and procedural efficiency in clinical practices, including colonoscopy and esophagogastroduodenoscopy, enhancing patient care outcomes.
• Fujifilm: Fujifilm’s CAD EYE technology focuses on early disease detection and diagnosis in gastrointestinal health. During the Asia Pacific Digestive Week 2023, Fujifilm showcased its commitment to advancing healthcare solutions. This innovative AI technology aids in detecting gastrointestinal cancers, reinforcing Fujifilm’s strategy to improve diagnostic accuracy and patient outcomes through cutting-edge medical solutions.
• Pentax Medical: Pentax Medical received CE mark approval for its Discovery AI-Assisted Polyp Detector, designed to support endoscopists in identifying potential polyps during colorectal examinations. This initiative underscores Pentax Medical’s focus on integrating AI into operating rooms to enhance clinical outcomes and patient care, particularly in the early and accurate detection of polyps.
• NEC Corporation: NEC Corporation introduced WISE VISION Endoscopy, an AI-powered diagnostic support software for colonoscopy, initially launched in Japan and soon to enter the European market. The software, trained on over 10,000 lesion images, seamlessly integrates with existing endoscopy systems to automatically detect potential lesions, supporting the early diagnosis of colorectal cancer. NEC’s innovation aims to improve diagnostic precision while offering a user-friendly interface to enhance medical care quality and patients’ quality of life.

Conclusion

The AI in endoscopy market is poised for significant growth, driven by advancements in diagnostic accuracy, operational efficiency, and personalized treatment strategies. AI-powered innovations, such as enhanced lesion detection, predictive analytics, and guided biopsies, are revolutionizing gastroenterology. Regulatory approvals and partnerships reflect robust adoption and innovation.

Key players like Medtronic, Olympus, and Fujifilm are advancing AI-integrated tools for improved patient outcomes. The market is projected to grow at a 30.6% CAGR from 2024 to 2033, reaching $838.9 million by 2033, with North America leading. AI’s transformative impact promises to enhance diagnostics, procedural efficiency, and education in gastrointestinal healthcare.

Discuss Your Needs With Our Analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF